Digoxin Administration: Clinical Decision-Making Beyond Heart Rate

Digoxin (digitalis) treats atrial fibrillation, atrial flutter, and heart failure by increasing cardiac contractility and controlling ventricular rate. However, a rapid apical heart rate alone does not determine whether digoxin is indicated.

Clinical Decision Framework

Assessment Before Administration

• Underlying rhythm: Is the tachycardia due to AF/flutter, or another cause (sepsis, anemia, hyperthyroidism, pain)?
• Hemodynamic stability: Is the patient hypotensive, showing signs of poor perfusion?
• Current medications: Beta-blockers, calcium channel blockers, amiodarone, diuretics (affecting electrolytes)
• Electrolyte status: Hypokalemia increases digoxin toxicity risk; hypercalcemia potentiates toxicity
• Renal function: Digoxin is renally excreted—dose adjustment required for CrCl <60 mL/min
• Symptom burden: Dyspnea, fatigue, exercise intolerance

Heart Rate Specifics

• AF/Flutter rate control target: Typically <100 bpm at rest (individualized)
• Rapid rate >100 bpm: Warrants evaluation but not automatic digoxin initiation
• Bradycardia <60 bpm: Hold digoxin and assess for toxicity

Monitoring & Safety

• Serum digoxin level: Therapeutic range 0.5-2 ng/mL (drawn 6+ hours post-dose)
• Daily apical pulse: Hold if <60 bpm (adults) or significant rhythm change
• Electrolytes & renal function: Monitor K+, Mg2+, CrCl regularly
• Toxicity signs: Nausea, visual changes (halos), confusion, arrhythmias

Key Takeaway

Digoxin initiation requires comprehensive clinical assessment—not just a heart rate number. Always consult the prescribing provider or clinical pharmacist for patient-specific decisions.